A phase II study if vedo in GvHD prevention was presented. This is of  major importance since we run the phase III vedo study. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Verigou

Results of the Prospective Randomized HOVON-96 Trial in Recipients of  Matched Related and Unrelated Donors were presented in ASH 2019, plenary  session PTCY is better than CSI standrd treatment https://ashpublications.org/blood/article-abstract/134/Supplement_1/1/427807/Post-Transplantation-Cyclophosphamide-after?redirectedFrom=fulltext Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Verigou

General principles - We use the lowest effective dose of prednisone or methylprednisolone. - We use topical therapy to supplement systemic treatment. (eg oral budesonide together with beclomethasone) -We use follow-up endoscopy to evaluate the response to treatment in patients with persistent diarrhea. Absence of clinical or...

NPM1_Spyridonidis_EAE_2019 Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou

A paper illustrating the hardle in making decisions in BMT. Presenter: Prof. Spyridonidis  Participants: Dr Liga, Dr Spyridis, Dr Verigou 

Presenter: Dr Liga Participants: Prof.Spyridonidis, Dr Spyridis, Dr Verigou

A retrospective matched paired analysis of  EBMT shows the superiority in  regards to GFRS of PTCY vs ATG in MMUD transplantation. Prospective  randomized should confirm these reults. Presenter: Prof.A Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou

In cases of relapse after allo-HCT, up to 50% of patients have cytogenetic or molecular evolution of their disease [15].A recent analysis in patients with MDS suggested that relapse after allo-HCT is driven by subclones evolving from founding clones existing before allo-HCT but harboring new aberrations [11], arguing for clonal...

Νεότερα δεδομένα στη θεραπευτική αντιμετώπιση της Οξείας Λεμφοβλαστικής Λευχαιμίας με τη σύγχρονη ανοσοθεραπεία. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou

Long term results of the phase III study were published. They confirm  our practice in  our Tx center Presenter: Prof. Spyridondis Particpants: Dr Liga, Dr Spyridis, Dr Verigou Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic  haemopoietic peripheral blood stem-cell transplantation from  HLA-identical siblings in patients with acute myeloid leukaemia...

Optimal conditioning for ALL. Does it exist?   Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou

Is an HLA-DRB1*1454/HLA-DRB1*1401 mismatchan acceptable mismatch in  hematopoietic stemcell transplantation? We discussed the role of such potential mismatches. We discussed the  G-coding and the imporance of typoing at exon 2 and 3 An abstract was presented Oudshoorn, Machteld & Lie, John & Roelen, Dave & Verduijn, Willem &  Claas, Frans....

We discussed a phase II study on LEN/AZa or treatment relapse after  transplantation.   Presenter:Prof Spyridonidis Participants:Dr Liga,Dr Spyridis, Dr Fragopanagou, Dr Verigou

We discussed a case of a young AML patient with  PTPN11 mutated (Glu76Lys, missense, NPM1 neg/ flt3 ITD neg) In a study (Hou et al, Leukemia volume 22, pages 1075–1078 (2008)  (https://doi.org/10.1182/blood-2018-99-110319) PTPN11 mutations were found in 5.1% adult AML patients and they were exclusively missense...

According to bibliography, G-CSF administration on day -1, 8 or during febrile neutropenia is not relevant with the progression of the disease. In contrast, G-CSF administration reduces TRM and can accelerate ANC recovery. As a result, we decided to administer G-CSF from day 15 (from the...

We presented a retospective analysis of BEAM vs BuCYVP16 in HL. BEAM conditioning before AHSCT resulted in a statistically significant  improved PFS and OS and lower relapse when compared with BUCYVP16.  Patients with shorter remission time from diagnosis and in non-CR at  time of AHSCT benefited most from...

When, Where, and How to use FLT3 inhibitors? What is their value? What are the open questions. Presenter:Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni